Editorji is a popular short video news and information platform based in India. It was founded in 2018 by Vikram Chandra, one of India’s leading journalists, and has risen to prominence in the digital news space in a relatively short span of time. The platform is primarily designed for mobile devices, with applications available for Android and iOS.

ABOUT US:

about us editorji

Latest Video News: Editorji provides the latest news video headlines, latest videos clip from India and the World. Get all breaking news videos on Entertainment, Business, Coronavirus, Elections, Politics and more.

Latest Video News, Breaking News, Bollywood, Political, Sports, Business News | Editorji

+91 11 4035 6666 / info@editorji.com
3rd floor, Plot B, Khasara no 360, Sultanpur, New Delhi, Delhi 110030
<a title="mail to us" href="mailto:info@editorji.com">Send Feedback</a>
<a title="Contact Us" href="mailto:info@editorji.com">Contact Us</a>

REACH US

Contact for any questions, suggestions, comments, feedback or advertisement on Editorji.com, we are always looking forward to hearing from you.

Contact Us for Feedback, Suggestions and Advertising 

Editorji content is better experienced in our app.

The Rs 1,500-crore-worth&nbsp;Glenmark&nbsp;Life IPO&nbsp;is oversubscribed by 50% on Day 1 as the investors look at the promising business ahead. From supplying&nbsp;API&nbsp;for a&nbsp;Covid&nbsp;drug to increasing manufacturing capacities, here's what is triggering the demand for the offering:
1. The company is expected to be supplying the API for Covid&nbsp;drug&nbsp;Favipiravir for Glenmark.
2. As on March 2021, the company has a portfolio of 120 molecules globally.&nbsp;16 of the 20 largest generic companies globally were its customers.
3. The future growth of its 120 molecules products is expected to remain stable driven by the increasing prevalence of non-communicable diseases like heart disease, stroke, cancer, diabetes and chronic lung disease.
4. The Company plans to increase its API manufacturing capabilities.
5.&nbsp;Expanding into Complex APIS such as oncology, iron replacement, peptides.

Glenmark Life IPO: Massive retail rush ovrsubscribed on Day 1, what's the buzz?

What's enthusing retail investors to Glenmark&nbsp;Life IPO. Here are 5 things you need to know to understand why the issue is getting oversubscribed.&nbsp;

Glenmark Life IPO subscribed 1.5x on Day 1; what is driving the interest

Glenmark&nbsp;Life is expected to be supplying the API for Covid&nbsp;drug&nbsp;Favipiravir for Glenmark

Retail investors are rushing towards the&nbsp;Rs 1,500-crore-worth&nbsp;Glenmark&nbsp;Life IPO&nbsp;which was full subscribed within hours of opening . So what is enthusing traders and investors in this pharma&nbsp;play Here is what you need to know about the Glemark Life-:
<ol>
<li>Growth Trigger: The company is expected to be supplying the API for Covid&nbsp;drug&nbsp;Favipiravir for Glenmark.</li>
<li>Promising Portfolio: With a strong showcase &nbsp;of 120 molecules globally.&nbsp;16 of the 20 largest generic companies globally were its customers.</li>
<li>Areas of Expertise: The future growth of its 120 molecules products is expected to remain stable driven by the increasing prevalence of non-communicable diseases like heart disease, stroke, cancer, diabetes and chronic lung disease.</li>
<li>Expansion: Plans to increase its API manufacturing capabilities.</li>
<li>Next Phase: Expanding into Complex APIs&nbsp;such as oncology, iron replacement, peptides.</li>
</ol>
Glenmark&nbsp;Life is also trading at a discount vs peers such as Divis&nbsp;Lab. The company will also be debt free post IPO&nbsp;and currently faces no regulatory issues on any of it's plants.&nbsp;

Glenmark&nbsp;Life Sciences'&nbsp;public issue or IPO&nbsp;will open on&nbsp;Tuesday&nbsp;and its scrips are already attracting a premium of over 20% in the grey markets. Here are all the details you need to know:
IPO&nbsp;issue date: July 27 to 29
Price band: Rs 695 to Rs 720 per equity share
Min quantity/lot size: 20 stocks
Lot price: Rs 13,900 (on lower price band)
IPO&nbsp;listing date: August 6, 2021
Grey market premium: Rs 150
Glenmark Life Sciences is a leading manufacturer of Active Pharmaceutical Ingredients (APIs). The company develops, manufactures, and supplies high-quality APIs for cardiovascular disease (CVS), central nervous system disease (CNS), pain management, and diabetes, gastrointestinal disorders, anti-infectives, and other therapeutic areas.

Glenmark Life IPO opens today; Here is the grey market premium and issue details 

Glenmark&nbsp;Life Sciences'&nbsp;public IPO&nbsp;opens today, with a grey market premium already at 20% should you be investing?

Glenmark&nbsp;Life Sciences'&nbsp;public issue or IPO&nbsp;will open on&nbsp;Tuesday&nbsp;and its scrips are already attracting a premium of over 20% in the grey markets. Here are all the details you need to know:
IPO&nbsp;issue date: July 27 to 29
Price band: Rs 695 to Rs 720 per equity share
Min quantity/lot size: 20 stocks
Lot price: Rs 13,900 (on lower price band)
IPO&nbsp;listing date: August 6, 2021
Grey market premium: Rs 150
Glenmark Life Sciences is a leading manufacturer of Active Pharmaceutical Ingredients (APIs). The company develops, manufactures, and supplies high-quality APIs for cardiovascular disease (CVS), central nervous system disease (CNS), pain management, and diabetes, gastrointestinal disorders, anti-infectives, and other therapeutic areas.

Glenmark Life Sciences is a leading manufacturer of Active Pharmaceutical Ingredients (APIs)

Glenmark&nbsp;Life Sciences'&nbsp;public issue or IPO&nbsp;opens on Tuesday and its scrips are already attracting a premium of over 20% in the grey markets. Here are all the details you need to know:
IPO&nbsp;issue date: July 27 to 29
Price band: Rs 695 to Rs 720 per equity share
Min quantity/lot size: 20 stocks
Lot price: Rs 13,900 (on lower price band)
Issue size: Rs 1,500 crore
IPO&nbsp;listing date: August 6, 2021
Grey market premium: Rs 150
Glenmark Life Sciences is a leading manufacturer of Active Pharmaceutical Ingredients (APIs). The company develops, manufactures, and supplies high-quality APIs for cardiovascular disease (CVS), central nervous system disease (CNS), pain management, and diabetes, gastrointestinal disorders, anti-infectives, and other therapeutic areas.

glenmark life sciences

Categories